{
  "id": 5729942,
  "title": "Lantheus alpha therapy, CATX director, sells $131k in stock",
  "url": "https://urgent.news/2026/09/05/lantheus-alpha-therapy-catx-director-sells-131k-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-05T05:46:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/lantheus-alpha-therapy-catx-director-sells-131k-in-stock-93CH-4890164"
  },
  "original_language": "en",
  "account": "Lantheus Alpha Therapy, LLC, a director and 10% owner of Perspective Therapeutics, Inc. (NASDAQ:CATX), divested shares amounting to $131,219 on September 2, 2026. The transaction entailed the sale of 42,129 shares of common stock, with prices fluctuating between $3.025 and $3.235 per share. The average sale price corresponded closely to the present stock value of $3.13, though the stock has fallen by 39% over the last six months and 49% under its 52-week peak of $6.16. As a result of this sale, Lantheus Alpha Therapy, LLC maintains a direct ownership of 11,521,296 shares of Perspective Therapeutics common stock. This entity is an indirect wholly-owned subsidiary of Lantheus Holdings, Inc., potentially implying indirect beneficial ownership of these shares. According to InvestingPro analysis, the stock seems overvalued in comparison to its estimated Fair Value. Despite a robust balance sheet with more liquid assets than financial obligations and a current ratio of 6.61, InvestingPro identifies the stock as having high volatility—among 10+ additional insights accessible to subscribers. Perspective Therapeutics Inc. has also been under scrutiny from various analysts. BMO Capital Markets initiated coverage with an Outperform rating and set a price target of $11. Piper Sandler, maintaining an Overweight rating, revised its price target from $16 to $14, following the company’s second-quarter 2026 earnings report. Perspective Therapeutics reaffirmed expectations for a significant site activation of bamzireotide navoxetan by the year’s end. BTIG reiterated a Buy rating and set a $14 price target, expressing optimism about the company as a significant pick for the second half of 2026. BTIG emphasized the company’s Pb-212 manufacturing infrastructure as a distinctive competitive advantage. These updates highlight the continuous interest and differing viewpoints from analysts on Perspective Therapeutics’ future outlook. This report was produced with AI support and reviewed by an editor. For further details, please refer to our Terms and Conditions.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}